This week SuperGut CEO Marc Washington joins the podcast to talk about why new GLP-1 drugs like Ozempic and Wegovy are keeping CPG brand CEOs up at night. These new drugs, which got their start as a new class of pharmaceuticals that help contol type 2 diabetes, have become very popular in recent years as weight loss drug. They are hugely effective in suppressing appetites and reducing the overall calorie intake of those taking them, so much so that some speculate that they could have a significant impact on overall demand for food if, as predicted, tens of millions begin to take them in coming years as the price comes down and more accessible formats (i.e. not shots) become available.   Marc thinks a lot about these drugs because his company, SuperGut, creates a natural alternative to GLP-1 drugs in the form of supplements, snacks and bars. His journey to leading the company was born out of both a personal loss as well as a chance meeting with Dave Friedberg, the CEO of The Production Board.  You can learn more about Super Gut on their website. And a quick plug before we go: The Spoon is heading up the food tech conference at CES, the world's biggest technology expo. If you'd like to become involved as a sponsor, just fill out this form and we'll be in touch!